Material Agreements

RLI CORP entered into 5.375% Senior Notes due 2036 Indenture with Computershare Trust Company, National Association valued at $300 million aggregate principal amount (effective 2026-03-03).

“On March 3, 2026, RLI Corp. (the “Company”) completed the public offering of $300 million in aggregate principal amount of its 5.375% Senior Notes due 2036 (the “Notes”). The Notes were issued pursuant to an indenture entered into on March 3, 2026 (the “Base Indenture”), as supplemented by a first supplemental indenture entered into on March 3, 2026 (the “First Supplemental Indenture”), in each case, between the Company and Computershare Trust Company, National Association, as trustee.”

REINSURANCE GROUP OF AMERICA INC entered into Twelfth Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $400 million (effective 2026-03-03).

“The Debentures were issued pursuant to an Indenture, dated as of August 21, 2012 (the “Base Indenture”), by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), as supplemented by a Twelfth Supplemental Indenture, dated as of March 3, 2026, by and between the Company and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture as so supplemented, the “Indenture”).”

KRATOS DEFENSE & SECURITY SOLUTIONS, INC. entered into Underwriting Agreement with Robert W. Baird & Co. Incorporated, as representative of the several underwriters valued at $84.00 per share (effective 2026-02-26).

“On February 26, 2026, Kratos Defense & Security Solutions, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Robert W. Baird & Co. Incorporated, as representative of the several underwriters named therein”

Crexendo, Inc. entered into Membership Interest Purchase Agreement with Estech Holdings, Inc. valued at $35,000,000 (effective 2026-03-01).

“On March 1, 2026, Crexendo, Inc. (the “ Company ”) entered into a Membership Interest Purchase Agreement (the “ Purchase Agreement ”) with Estech Holdings, Inc., a Texas corporation (“ Seller ”), and the individuals listed therein, pursuant to which the Company agreed to purchase from Seller one hundred percent (100%) of the issued and outstanding membership interests (the “ Purchased Interests ”) of Estech Systems, LLC, a Delaware limited liability company, and its operating subsidiary, ESI Hosted Services, LLC (collectively, the “ Target ”), subject to the terms and conditions set forth in the Purchase Agreement (the “ Acquisition ”).”

GYRE THERAPEUTICS, INC. entered into Registration Rights Agreement with Cullgen, Inc. and certain holders of Cullgen Capital Stock valued at Undisclosed.

“In connection with the closing of the Merger, the Company will enter into a Registration Rights Agreement (the “Registration Rights Agreement”) with Cullgen and certain holders of shares of Cullgen Capital Stock signatory thereto (the “Company Holders”).”

GYRE THERAPEUTICS, INC. entered into Lock-Up Agreements with Certain executive officers, directors and stockholders of Company and Cullgen valued at Undisclosed (effective 2026-03-02).

“Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of the Company and Cullgen have entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Company Common Stock (or shares convertible for Company Common Stock) for (a) with respect to one-third of the shares of Company Common Stock held by them, the 180-day period following the Merger Closing Date, (b) with respect to one-third of the shares of Company Common Stock held by them, the twelve-month period following the Merger Closing Date, and (c) with respect to one-third of the shares of Company Common Stock held by them, the eighteen month period following the Merger Closing Date.”

GYRE THERAPEUTICS, INC. entered into Support Agreements with Cullgen, Inc. and certain stockholders valued at Undisclosed (effective 2026-03-02).

“Concurrently with the execution of the Merger Agreement, (i) certain officers, directors, and stockholders of the Company (solely in their respective capacities as Company stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Company Common Stock in favor of the Conversion Proposal (the “Company Support Agreement”), and (ii) certain officers, directors and stockholders of Cullgen (solely in their respective capacities as Cullgen stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Cullgen Capital Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the “ Cullgen Support Agreement” and together with the Company Support Agreement, the “ Support Agreements”).”

GYRE THERAPEUTICS, INC. entered into Merger Agreement with Cullgen, Inc. valued at Undisclosed (effective 2026-03-02).

“Each of the Company and Cullgen has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1) using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2) non-solicitation of alternative acquisition proposals, (3) the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, and (4) the Company filing with the U.S. Securities and Exchange Commission (the “SEC”) a proxy statement and other relevant materials relating to the Conversion Proposal (as defined below).”

Targa Resources Corp. entered into Thirteenth Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $750.0 million aggregate principal amount of the Company’s 4.350% Senior Notes due 2031 and $750.0 m (effective 2026-03-02).

“On March 2, 2026, Targa Resources Corp. (the “Company”), along with certain of its subsidiaries (the “Subsidiary Guarantors”), completed the previously announced underwritten public offering (the “Offering”) of (i) $750.0 million aggregate principal amount of the Company’s 4.350% Senior Notes due 2031 (the “2031 Notes”) and (ii) $750.0 million aggregate principal amount of the Company’s 6.050% Senior Notes due 2056 (the “2056 Notes,” and, together with the 2031 Notes, the “Notes”).”

DHI GROUP, INC. entered into Membership Interest Purchase Agreement with selling members of Point Solutions Group, LLC valued at approximately $5.5 million (effective 2026-02-27).

“On February 27, 2026 ClearanceJobs, LLC, a recently formed Delaware limited liability company and a wholly owned indirect subsidiary of DHI Group, Inc., (the “Company”) entered into, and closed the transactions contemplated by, a Membership Interest Purchase Agreement (the “Agreement”) with the selling members (collectively, the “Sellers”) of Point Solutions Group, LLC”

DUOS TECHNOLOGIES GROUP, INC. entered into Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the sole bookrunner valued at approximately $65 million (effective 2026-02-26).

“☐ Item 1.01 Entry Into a Material Definitive Agreement On February 26, 2026, Duos Technologies Group, Inc. (the “Company”) priced its recently announced public offering (the “Offering”) of common stock, par”

Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.

“On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).”

Booz Allen Hamilton Holding Corp entered into Eleventh Amendment to the Credit Agreement with Bank of America, N.A. valued at aggregate revolving commitments of $1.5 billion and Tranche A-2 Term Loan of $750 million (effective 2026-02-27).

“On February 27, 2026 (the “Eleventh Amendment Effective Date”), Booz Allen Hamilton Holding Corporation and its wholly-owned subsidiary Booz Allen Hamilton Inc. (the “Company”) entered into an eleventh amendment (the “Eleventh Amendment”) to the Credit Agreement, dated as of July 31, 2012”

FIDUS INVESTMENT Corp amended Equity Distribution Agreement Amendment No. 3 with Raymond James & Associates, Inc.; B. Riley Securities, Inc. valued at ATM Program maximum increased to $400.0 million; approx. $134.8 million remaining available (effective 2026-03-02).

“On March 2, 2026, the Company increased the maximum amount of Shares to be sold through the ATM Program to $400.0 million from $300.0 million. In connection with the upsize of the ATM Program, the Company entered into amendment no. 3 (“Amendment No. 3”) to the equity distribution agreement, dated November 10, 2022 (the “Equity Distribution Agreement”) with Fidus Investment Advisors, LLC, Raymond James & Associates, Inc. (“Raymond James”) and B. Riley Securities, Inc. (“B. Riley” and together with Raymond James, the “Sales Agents”).”

MARIMED INC. entered into Restructuring and Exchange Agreement with Navy Capital Green International, Ltd. valued at $8,000,000 (effective 2026-02-24).

“On February 24, 2026, the Company and Navy entered into a Restructuring and Exchange Agreement (the “Restructuring and Exchange Agreement”) to address and restructure the Series B Obligation”

Chaince Digital Holdings Inc. entered into Securities Purchase Agreement with certain non-U.S. investors valued at $5,031,000 (effective 2026-02-25).

“On February 25, 2026 (the "Execution Date"), Chaince Digital Holdings Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain non-U.S. investors (the "Purchasers"), pursuant to which the Comnpany agreed to sell an aggregate of 6,500,000 ordinary shares of the Company par value $0.004 per share, at a purchanse price of $0.774 per ordinary share, for a total purchase price of $5,031,000 (the "Offering"), in reliance upon the exemption provided by Rule 903 of Regulation S promulgated under the Securities Act of 1933, as amended.”

Voya Financial, Inc. entered into Tenth Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $400 million aggregate principal amount (effective 2026-03-02).

“The Notes and Guarantee were issued pursuant to the Indenture dated as of July 13, 2012 (the “Base Indenture”), as supplemented by a Tenth Supplemental Indenture dated as of March 2, 2026 (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), each among Voya, Voya Holdings and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”

HA Sustainable Infrastructure Capital, Inc. entered into Indenture and 6.000% Green Senior Unsecured Notes due 2036 with U.S. Bank Trust Company, National Association valued at $400,000,000 aggregate principal amount of 6.000% Green Senior Unsecured Notes due 2036 (effective 2026-03-02).

“On March 2, 2026, HA Sustainable Infrastructure Capital, Inc., a Delaware corporation (the “Company”), issued $400,000,000 aggregate principal amount of its 6.000% Green Senior Unsecured Notes due 2036 (the “Notes”), under an indenture, dated as of June 24, 2025 (the “Base Indenture”), between the Company, Hannon Armstrong Sustainable Infrastructure, L.P., a Delaware limited partnership (the “Operating Partnership”), Hannon Armstrong Capital, LLC, a Maryland limited liability company (“HAC”), HAT Holdings I LLC, a Maryland limited liability company (“HAT I”), HAT Holdings II LLC, a Maryland limited liability company (“HAT II”), HAC Holdings I LLC, a Delaware limited liability company (“HAC Holdings I”) and HAC Holdings II LLC, a Delaware limited liability company (“HAC Holdings II,” and collectively with the Operating Partnership, HAC, HAT I, HAT II and HAC Holdings I, the “Guarantors”), as guarantors, and U.S. Bank Trust Company, National Association, as trustee, as amended and supple”

Pulmatrix, Inc. terminated Agreement and Plan of Merger and Reorganization with Cullgen Inc. (effective 2026-02-28).

“Pulmatrix, Inc. (the “ Company ” or “ Pulmatrix ”) received a termination notice (the “ Notice ”) from Cullgen Inc. (“ Cullgen ”) pursuant to which Cullgen informed the Company that in accordance with Sections 11.7 and 10.1(b) of that certain Agreement and Plan of Merger and Reorganization, dated as of November 13, 2024, as amended by Amendment No. 1 thereto dated as of April 7, 2025 (the “ Merger Agreement ”), by and among the Company, Pulmatrix and PCL Merger Sub, Inc. and PCL Merger Sub Inc. II, LLC, Cullgen was terminating the Merger Agreement and all related transactions thereunder.”

Purebase Corp entered into Line of Credit Agreement and unsecured promissory note with CorTer, LLC valued at Line of credit of up to $1,000,000; Note bears interest at 8% per annum, matures February 27, 2027 (effective 2026-02-27).

“On February 27, 2026, Purebase Corporation, a Nevada corporation (the “Company”) entered into a line of credit agreement (the “Line of Credit Agreement”) with CorTer, LLC, a Nevada limited liability company (“CoreTer”) which is owned and managed by A. Scott Dockter, the Company’s Chief Executive Officer, under which CoreTer agreed to make an unsecured loan to the Company of up to $1,000,000 until February 27, 2027.”

TriplePoint Venture Growth BDC Corp. entered into 2026 Master Note Purchase Agreement valued at $75,000,000 (effective 2026-02-27).

“On February 27, 2026, TriplePoint Venture Growth BDC Corp. (the “Company”) entered into a Master Note Purchase Agreement (the “2026 Master Note Purchase Agreement”) governing the issuance of $75,000,000 in aggregate principal amount of senior unsecured notes due February 27, 2028”

MALIBU BOATS, INC. entered into Securities Purchase Agreement with Saxdor Yachts Oy and the stockholders and option right holders of Saxdor valued at €150,000,000 or approximately $175,000,000 (effective 2026-03-02).

“On March 2, 2026 (the “Closing Date”), Malibu Boats, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Saxdor Yachts Oy, a Finnish limited company (“Saxdor”), and the stockholders and option right holders of Saxdor (the “Sellers”).”

Sabre Corp entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2026-03-01).

“the Company entered into a Rights Agreement (the “Rights Agreement”), dated as of March 1, 2026, between the Company and Equiniti Trust Company, LLC, as rights agent.”

Avalon GloboCare Corp. entered into Purchase Agreements with certain institutional investors (effective 2026-02-26).

“On February 26, 2026, Avalon GloboCare Corp. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors”

Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at $1,035,316,650 (effective 2026-03-02).

“On March 2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $750,000,000 to $1,035,316,650.”

UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).

“On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).”

Eton Pharmaceuticals, Inc. entered into Licensing Agreement with Pierre Fabre Medicament Sas valued at $14.0 million upfront (effective 2026-02-27).

“On February 27, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a licensing agreement and acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”).”

Tilray Brands, Inc. entered into Business and Asset Sale Agreement with BrewDog plc and certain of its subsidiary undertakings (collectively, the "BrewDog Group") valued at £33,000,000 (or approximately US $44.1 million) (effective 2026-03-02).

“On March 2, 2026, Tilray Brands UK Ltd (“ Tilray UK ”), a company registered in the United Kingdom and wholly owned and controlled by Tilray Brands, Inc. (the “ Company ”), entered into a Business and Asset Sale Agreement (the “ Purchase Agreement ”).”

Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).

“On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)”

Our Bond, Inc. entered into Promissory Note with Ascent Partners Fund, LLC valued at Principal amount of $2,500,000, interest at 10% per annum, matures September 1, 2026 (effective 2026-03-01).

“Also on March 1, 2026, we issued a Promissory Note to Ascent Partners Fund, LLC in the principal amount of $2,500,000 (the "Note").”

Our Bond, Inc. amended Amendment No. 1 to Warrants to Purchase Shares of Common Stock valued at Exercise price reduced for 12,000,000 shares: 4,500,000 shares at $2.25 per share, 3,750,000 shares (effective 2026-03-01).

“On March 1, 2026, Our Bond, Inc., a Nevada corporation ("we," "us," "our" or the "Company") entered into Amendment No. 1 (the "Amendment") to the terms of one of our outstanding Warrants to Purchase Shares of Common Stock issued October 27, 2025 (the "Warrant").”

Acrivon Therapeutics, Inc. terminated OncoSignature Companion Diagnostic Agreement with Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation) (effective 2026-02-25).

“On February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into a Termination and Transition Agreement pursuant to which they have mutually agreed to terminate (the “termination”) the OncoSignature Companion Diagnostic Agreement, dated June 17, 2022, by and between the Company and Akoya.”

GeneDx Holdings Corp. terminated Existing Credit Agreement with Perceptive Credit Holdings IV, LP valued at Repayment in full of existing term loan (effective 2026-02-27).

“The proceeds of the Term Loan were used to repay in full the Company’s existing term loan under its existing Credit Agreement and Guaranty, dated as of October 27, 2023, by and among Sema4 OpCo, Inc. and GeneDx, LLC, as Borrowers, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP as the administrative agent and as a lender (the “Existing Credit Agreement”)”

GeneDx Holdings Corp. entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. valued at $100.0 million term loan (effective 2026-02-27).

“On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries of the Company party thereto as Guarantors, Wilmington Trust, National Association, as Agent and the lenders from time to time party thereto (collectively, the “Lenders”).”

Bakkt, Inc. entered into Purchase Agreement with a single investor valued at approximately $48.125 million (effective 2026-02-27).

“On February 27, 2026, Bakkt, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Investor”), pursuant to which the Company agreed to sell and issue to the Investor an aggregate of 3,024,799 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 2,475,201 shares of Common Stock (the “Offering”).”

Fortitude Gold Corp entered into Joint Venture Agreement with Hawthorne Land & Minerals, LLC valued at $40 million (effective 2026-02-27).

“On February 27, 2026, Fortitude Gold Corp. (the “Company” or “Fortitude”) entered into a Joint Venture Agreement (the “JV Agreement”) with Hawthorne Land & Minerals, LLC (“Hawthorne”) to accelerate the exploration and development of its East Camp Douglas property located in Mineral County, Nevada.”

Fortress Value Acquisition Corp. V entered into Administrative Services Agreement with FIG LLC valued at Administrative services agreement (effective 2026-02-25).

“An Administrative Services Agreement, dated February 25, 2026, by and between the Company and FIG LLC, a copy of which is attached as Exhibit 10.5 hereto and incorporated herein by reference.”

Fortress Value Acquisition Corp. V entered into Letter Agreement with Sponsor and each officer and director valued at Letter agreement among company, officers, directors, and sponsor (effective 2026-02-25).

“Letter Agreement, dated February 25, 2026, between the Company, each of its officers and directors, and the Sponsor, a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.”

Fortress Value Acquisition Corp. V entered into Private Placement Shares Purchase Agreement with Fortress Value Acquisition Sponsor V LLC valued at Private placement shares purchase (effective 2026-02-25).

“A Private Placement Shares Purchase Agreement, dated February 25, 2026 (the “ Private Placement Shares Purchase Agreement ”), by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.”

Fortress Value Acquisition Corp. V entered into Registration Rights Agreement with Fortress Value Acquisition Sponsor V LLC and certain other securities holders valued at Registration rights agreement (effective 2026-02-25).

“A Registration Rights Agreement, dated February 25, 2026, among the Company, Fortress Value Acquisition Sponsor V LLC (the “ Sponsor ”) and certain other securities holders named therein, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference.”

Fortress Value Acquisition Corp. V entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at Trust agreement in connection with IPO (effective 2026-02-25).

“An Investment Management Trust Agreement, February 25, 2026, by and between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.”

Fortress Value Acquisition Corp. V entered into Underwriting Agreement with Deutsche Bank Securities Inc. valued at $250,000,000 gross proceeds from IPO of 25,000,000 Class A ordinary shares at $10.00 per share (effective 2026-02-25).

“tatement: ● An Underwriting Agreement, dated February 25, 2026, by and between the Company and Deutsche Bank Securities Inc., a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.”

Keen Vision Acquisition Corp. terminated Prior Merger Agreement with Medera Inc. and Novoheart Group Limited valued at Prior Merger Agreement dated September 3, 2024 was terminated concurrently with execution of the LOI (effective 2026-02-26).

“The LOI replaces the prior Merger Agreement dated September 3, 2024, which was terminated concurrently with execution of the LOI pursuant to a mutual release agreement entered into by the parties.”

Keen Vision Acquisition Corp. entered into Binding Letter of Intent with Medera Inc. and Novoheart Group Limited valued at Enterprise valuation of Novoheart Group Limited set at US$100,000,000; surviving company must have a (effective 2026-02-26).

“On February 26, 2026, Keen Vision Acquisition Corporation, a British Virgin Islands business company limited by shares (“Parent”), entered into a binding letter of intent (“LOI”) with Medera Inc., a Cayman Islands exempted company (“Company”), and Novoheart Group Limited, a British Virgin Islands company and wholly owned subsidiary of the Company (“NVH”).”

Signing Day Sports, Inc. terminated At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-02-27).

“On February 27, 2026, the Company delivered a Notice of Termination to the Sales Agent terminating the Sales Agreement as of March 10, 2026.”

Zymeworks Inc. entered into Loan Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).

“Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).”

Zymeworks Inc. entered into Sale Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).

“On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.”

Kairos Pharma, LTD. entered into Binding Term Sheet with Celyn Therapeutics, Inc. valued at Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston (effective 2026-03-02).

“On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company (“Celyn”), regarding a proposed asset acquisition of CL-273 (the “Asset Acquisition”), an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed by Eilean Therapeutics for EGFR mutant non small cell lung cancer (the “Term Sheet”).”

Classover Holdings, Inc. terminated Equity Purchase Facility Agreement with Solana Strategic Holdings LLC valued at $400 million (effective 2026-02-28).

“(the “Company”) entered into an Equity Purchase Facility Agreement (the “EPFA”) with Solana Strategic Holdings LLC (the “Investor”) pursuant to which, subject to certain conditions precedent contained therein, the Company had the right to issue and sell to the Investor up to an aggregate of $400 million in newly issued shares of the Company’s Class B common stock, par value $0.0001 per share (the “Shares”).”

Paramount Skydance Corp entered into Agreement and Plan of Merger with Warner Bros. Discovery, Inc. (effective 2026-02-27).

“On February 27, 2026, Warner Bros. Discovery, Inc., a Delaware corporation (“WBD”), Paramount Skydance Corporation, a Delaware corporation (“PSKY”), and Prince Sub Inc., a Delaware corporation and wholly owned subsidiary of PSKY (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which and subject to the terms and conditions therein, at the effective time of the Merger (as defined below) (the “Effective Time”), Merger Sub will merge with and into WBD, with WBD surviving as a wholly owned subsidiary of PSKY (the “Merger”).”